Company Description

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED).

Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Acelyrin, Inc.

Country	United States
Founded	2020
IPO Date	May 5, 2023
Industry	Biotechnology
Sector	Healthcare
Employees	83
CEO	Mina Kim

Contact Details

Address: 4149 Liberty Canyon Road Agoura Hills, California 91301 United States
Phone	805 456 4393
Website	acelyrin.com

Stock Details

Ticker Symbol	SLRN
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$18.00
CIK Code	0001962918
CUSIP Number	00445A100
ISIN Number	US00445A1007
Employer ID	85-2406735
SIC Code	2834

Key Executives

Name	Position
Mina Kim J.D.	Chief Executive Officer and Director
Dr. Shephard Mpofu M.D.	Chief Medical Officer
Tyler Marciniak	Vice President of Investor Relations, Communications and Corporate Operations
K. Amar Murugan J.D.	Chief Legal Officer
Kelly Chow	Chief People Officer
Kenneth A. Lock	Chief Commercial Officer
Patricia A. Turney	Chief Technical Operations Officer

Latest SEC Filings

Date	Type	Title
Apr 23, 2025	DEFR14A	Filing
Apr 21, 2025	425	Filing
Apr 21, 2025	425	Filing
Apr 21, 2025	425	Filing
Apr 21, 2025	425	Filing
Apr 21, 2025	8-K	Current Report
Apr 4, 2025	425	Filing
Apr 4, 2025	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 4, 2025	DEFM14A	Filing
Mar 25, 2025	425	Filing

View All SEC Filings